NCT05566002 Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension
| NCT ID | NCT05566002 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese Pulmonary Vascular Disease Research Group |
| Condition | Pulmonary Hypertension |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2022-06-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2022-06-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pulmonary hypertension represents a challenging and heterogeneous condition that is associated with high mortality and morbidity if left untreated. Artificial intelligence is used to study and develop theories and methods that simulate and extend human intelligence, which is being applied in fields related to cardiovascular diseases. The study intends to combine multimodal clinical data of patients who undergo right heart catheterization at Fuwai Hospital with artificial intelligence techniques to create programs that can screen and diagnose pulmonary hypertension.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years old * Patients previously received chest X-ray, electrocardiography, echocardiography, other routine examinations, and RHC at the Fuwai Hospital, CAMS \& PUMC, Beijing, China Exclusion Criteria: * Patients without RHC * The quality of routine examinations and RHC cannot meet the requirement for further analysis * Severe loss of results of routine examinations (chest X-ray, electrocardiography, echocardiography, etc.)
Contact & Investigator
Zhihong Liu, MD, PhD
PRINCIPAL INVESTIGATOR
Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Frequently Asked Questions
Who can join the NCT05566002 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pulmonary Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05566002 currently recruiting?
Yes, NCT05566002 is actively recruiting participants. Contact the research team at zhihongliufuwai@163.com for enrollment information.
Where is the NCT05566002 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT05566002 clinical trial?
NCT05566002 is sponsored by Chinese Pulmonary Vascular Disease Research Group. The principal investigator is Zhihong Liu, MD, PhD at Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. The trial plans to enroll 2,000 participants.